Andrew E. Nixon

2.5k total citations
44 papers, 1.3k citations indexed

About

Andrew E. Nixon is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Andrew E. Nixon has authored 44 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 20 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Immunology. Recurrent topics in Andrew E. Nixon's work include Monoclonal and Polyclonal Antibodies Research (20 papers), Protein purification and stability (9 papers) and Viral Infectious Diseases and Gene Expression in Insects (8 papers). Andrew E. Nixon is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (20 papers), Protein purification and stability (9 papers) and Viral Infectious Diseases and Gene Expression in Insects (8 papers). Andrew E. Nixon collaborates with scholars based in United States, Austria and Germany. Andrew E. Nixon's co-authors include Stephen J. Benkovic, Daniel J. Sexton, Marc Ostermeier, Robert C. Ladner, Steven M. Firestine, Jae Hoon Shim, Justin M. Scheer, Martin R. Webb, Arthur C. Ley and Frank Salinas and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and SHILAP Revista de lepidopterología.

In The Last Decade

Andrew E. Nixon

44 papers receiving 1.2k citations

Peers

Countries citing papers authored by Andrew E. Nixon

Since Specialization

Citations

This map shows the geographic impact of Andrew E. Nixon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew E. Nixon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew E. Nixon more than expected).

Fields of papers citing papers by Andrew E. Nixon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew E. Nixon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew E. Nixon. The network helps show where Andrew E. Nixon may publish in the future.

Co-authorship network of co-authors of Andrew E. Nixon

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew E. Nixon. A scholar is included among the top collaborators of Andrew E. Nixon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew E. Nixon. Andrew E. Nixon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Deep learning-based design and experimental validation of a medicine-like human antibody library 2024 ·Briefings in Bioinformatics ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Alexander M. Horspool, (unknown), Peter M. Tessier, Michael S. Marlow, Andrew E. Nixon, Sandeep Kumar	3
2	Programmed Cell Death-1 (PD-1) anchoring to the GPI-linked co-receptor CD48 reveals a novel mechanism to modulate PD-1-dependent inhibition of human T cells 2023 ·Molecular Immunology ·(unknown), (unknown), (unknown), (unknown), (unknown), Helen L. Wu, Dongmei Liu, David Young, Justin K. Scheer, Ivo C. Lorenz, Andrew E. Nixon, Jay S. Fine, Fergus R. Byrne, (unknown), Miguel E. Moreno‐García	7
3	How can we discover developable antibody-based biotherapeutics? 2023 ·Frontiers in Molecular Biosciences ·(unknown), (unknown), Priyanka Gupta, Pankaj Gupta, Andrew E. Nixon, Sandeep Kumar	17
4	A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer 2020 ·Clinical Cancer Research ·Susanne Hipp, Vladimir Voynov, Barbara Drobits, Craig Giragossian, Francesca Trapani, Andrew E. Nixon, Justin M. Scheer, Paul J. Adam	67
5	Choices of capture chromatography technology in antibody manufacturing processes 2017 ·Journal of Chromatography B ·(unknown), Arthur C. Ley, Andrew E. Nixon, Jie Chen	17
6	Structural basis for pH-insensitive inhibition of immunoglobulin G recycling by an anti-neonatal Fc receptor antibody 2017 ·Journal of Biological Chemistry ·Jon Kenniston, (unknown), (unknown), (unknown), (unknown), (unknown), Stephen R. Comeau, Kateri Atkins, (unknown), Christopher TenHoor, Burt Adelman, Daniel J. Sexton, Thomas E. Edwards, Andrew E. Nixon	11
7	Fully Human Monoclonal Antibody Inhibitors of the Neonatal Fc Receptor Reduce Circulating IgG in Non-Human Primates 2015 ·Frontiers in Immunology ·Andrew E. Nixon, Jie Chen, Daniel J. Sexton, Arumugam Muruganandam, Alan J. Bitonti, Jennifer Dumont, Malini Viswanathan, Diana Martik, Dina Wassaf, Adam R. Mezo, Clive R. Wood, Joseph C. Biedenkapp, Chris TenHoor	48
8	Comparison Of Plasma Kallikrein Inhibition By The Monoclonal Antibody Inhibitor DX-2930 To Endogenous C1-INH 2014 ·Journal of Allergy and Clinical Immunology ·Daniel J. Sexton, Jon Kenniston, Ryan Faucette, Andrew E. Nixon, Christopher TenHoor, Yung Chyung, Burt Adelman	1
9	A homogeneous fluorescence anisotropy assay for measuring transglutaminase 2 activity 2013 ·Analytical Biochemistry ·Jon Kenniston, (unknown), Daniel J. Sexton, Andrew E. Nixon	9
10	The distinctive separation attributes of mixed-mode resins and their application in monoclonal antibody downstream purification process 2009 ·Journal of Chromatography A ·Jie Chen, (unknown), Yanyu Zhang, (unknown), Greg Conley, (unknown), (unknown), Andrew E. Nixon, Arthur C. Ley	116
11	Rapid kinetic-based screening of human Fab fragments 2006 ·Journal of Immunological Methods ·Mieke Steukers, (unknown), Reinoud van Gool, Anne Hoyoux, (unknown), Daniel J. Sexton, Andrew E. Nixon, Marc Vanhove	16
12	Phage Display as a Tool for Protease Ligand Discovery 2002 ·Current Pharmaceutical Biotechnology ·Andrew E. Nixon	21
13	Rational and “Irrational” Design of Proteins and Their Use in Biotechnology 2000 ·IUBMB Life ·Andrew E. Nixon, Steven M. Firestine	8
14	Using an AraC-based three-hybrid system to detect biocatalysts in vivo 2000 ·Nature Biotechnology ·Steven M. Firestine, Frank Salinas, Andrew E. Nixon, Stephen J. Baker, Stephen J. Benkovic	43
15	Improvement in the efficiency of formyl transfer of a GAR transformylase hybrid enzyme 2000 ·Protein Engineering Design and Selection ·Andrew E. Nixon, Stephen J. Benkovic	9
16	Incremental truncation as a strategy in the engineering of novel biocatalysts 1999 ·Bioorganic & Medicinal Chemistry ·Marc Ostermeier, Andrew E. Nixon, Stephen J. Benkovic	42
17	Hybrid enzymes: manipulating enzyme design 1998 ·Trends in biotechnology ·Andrew E. Nixon, Marc Ostermeier, Stephen J. Benkovic	67
18	Purine Nucleoside Phosphorylase: Its Use in a Spectroscopic Assay for Inorganic Phosphate and for Removing Inorganic Phosphate with the Aid of Phosphodeoxyribomutase 1998 ·Analytical Biochemistry ·Andrew E. Nixon, Jackie L. Hunter, (unknown), John F. Eccleston, Martin R. Webb	37
19	Threading your way to protein function 1996 ·Chemistry & Biology ·Steven M. Firestine, Andrew E. Nixon, Stephen J. Benkovic	6
20	Kinetics of Inorganic Phosphate Release during the Interaction of p21ras with the GTPase-Activating Proteins, p120-GAP and Neurofibromin 1995 ·Biochemistry ·Andrew E. Nixon, Martin Brune, Peter N. Lowe, Martin R. Webb	48

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact